Is Tivozanib effective in treating osteosarcoma?

Tivozanib is approved to treat advanced renal cell carcinoma (a type of kidney cancer) in adults whose disease has relapsed or is refractory (not responding to treatment) after at least two other types of systemic therapy. Tivozanib is also being studied to treat other types of cancer. Tivozanib's efficacy in osteosarcoma has not yet been fully studied and confirmed.

Osteosarcoma is the most common primary bone malignant tumor. The treatment model of osteosarcoma has not made much progress. Treatment includes neoadjuvant chemotherapy, surgery and postoperative chemotherapy. The 5-year survival rate of patients is about 60%. So far, tki has been reported in clinical trials of patients with osteosarcomaIncludingAxitinib, Cabozantinib, Cediranib, etc. TKIs are targeted drugs that can specifically inhibit protein tyrosine kinases (PTKs). Recent clinical trials have shown that several multi-target tyrosine kinase inhibitors (TKIs) can effectively treat osteosarcoma. Tivozanibis a potent and highly selectiveVEGFR TKI with activity against all three VEGFRs and therefore may be a potential new drug for the treatment of metastatic sarcoma. If the patient suffers from osteosarcoma, it is recommended to consult a professional doctor or oncologist in a timely manner to obtain the most accurate treatment advice, and not to use medication at will.

The original drug Tivozanib has not yet been marketed in the country, so it has not been included in medical insurance. The European version of tivozanib Original drug, specifications1340mcg*21 pills sold overseas may cost around 30,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic version of tivozanib available on the market. For more drug information and specific prices, please consult a medical consultant.